A Phase 1, Single-Dose, Open-Label Trial to Evaluate the Pharmacokinetics and Safety of AG-120 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Cholangiocarcinoma; Glioma; Myelodysplastic syndromes; Solid tumours
- Focus Pharmacokinetics
- Sponsors Agios Pharmaceuticals
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Mar 2017 Status changed from not yet recruiting to recruiting.